[go: up one dir, main page]

EG24225A - Solid lipid formulations - Google Patents

Solid lipid formulations

Info

Publication number
EG24225A
EG24225A EG20001160A EG20001160A EG24225A EG 24225 A EG24225 A EG 24225A EG 20001160 A EG20001160 A EG 20001160A EG 20001160 A EG20001160 A EG 20001160A EG 24225 A EG24225 A EG 24225A
Authority
EG
Egypt
Prior art keywords
solid lipid
lipid formulations
formulations
solid
lipid
Prior art date
Application number
EG20001160A
Other languages
English (en)
Inventor
De Smidt C Passchier
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG24225(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of EG24225A publication Critical patent/EG24225A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
EG20001160A 1999-09-13 2000-09-12 Solid lipid formulations EG24225A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99118179 1999-09-13

Publications (1)

Publication Number Publication Date
EG24225A true EG24225A (en) 2008-11-10

Family

ID=8238989

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20001160A EG24225A (en) 1999-09-13 2000-09-12 Solid lipid formulations

Country Status (36)

Country Link
US (1) US6703369B1 (xx)
EP (1) EP1216048B1 (xx)
JP (1) JP4217017B2 (xx)
KR (1) KR100523879B1 (xx)
CN (1) CN1197554C (xx)
AR (1) AR025609A1 (xx)
AT (1) ATE285783T1 (xx)
AU (1) AU769016B2 (xx)
BR (1) BRPI0013940B1 (xx)
CA (1) CA2383036C (xx)
CO (1) CO5210857A1 (xx)
CZ (1) CZ301844B6 (xx)
DE (1) DE60017156T2 (xx)
EG (1) EG24225A (xx)
ES (1) ES2233444T3 (xx)
GC (1) GC0000259A (xx)
HK (1) HK1049798B (xx)
HR (1) HRP20020206B1 (xx)
HU (1) HU229037B1 (xx)
IL (2) IL148570A0 (xx)
JO (1) JO2300B1 (xx)
MA (1) MA26817A1 (xx)
ME (1) ME00675B (xx)
MX (1) MXPA02002662A (xx)
MY (1) MY127430A (xx)
NO (1) NO328889B1 (xx)
NZ (1) NZ517396A (xx)
PE (1) PE20010661A1 (xx)
PL (1) PL199869B1 (xx)
PT (1) PT1216048E (xx)
RS (1) RS50373B (xx)
RU (1) RU2248218C2 (xx)
SI (1) SI1216048T1 (xx)
TR (1) TR200200605T2 (xx)
WO (1) WO2001019378A2 (xx)
ZA (1) ZA200201249B (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
KR100572785B1 (ko) * 2000-07-28 2006-04-19 에프. 호프만-라 로슈 아게 신규한 약학 조성물
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
DE10251963A1 (de) * 2002-11-08 2004-05-19 Lts Lohmann Therapie-Systeme Ag Transmucosale pharmazeutische Darreichungsform
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
AU2003225649C1 (en) * 2003-03-04 2009-10-22 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
FI20045076L (fi) * 2004-03-15 2005-09-16 Bioferme Oy Funktionaalinen elintarvike
CA2582767C (en) * 2004-10-25 2011-05-24 Japan Tobacco Inc. Solid formulation with improved solubility and stability and method for producing said formulation
KR100669497B1 (ko) * 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
EP1808163A1 (en) * 2005-12-22 2007-07-18 Teva Pharmaceutical Industries Ltd. Compressed solid dosage forms with drugs of low solubility and process for making the same
CA2626234A1 (en) * 2005-12-22 2007-06-28 Teva Pharmaceutical Industries Ltd. Compressed solid dosage forms with drugs of low solubility and process for making the same
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
KR101252635B1 (ko) 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
KR100903504B1 (ko) * 2007-05-18 2009-06-17 강태용 비라칸사스 열매 추출물질을 포함하는 기능식품 및 체중 감소제
EP2076248A2 (en) * 2007-08-17 2009-07-08 Teva Pharmaceutical Industries Ltd. Methods and compositions for controlling the bioavailability of poorly soluble drugs
ATE477820T1 (de) * 2007-09-12 2010-09-15 Mader S R L Pharmazeutische zusammensetzungen zur oralen verabreichung bei der behandlung von adipositas- patienten
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
US8309107B2 (en) 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
BRPI0901602B8 (pt) 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
UA107369C2 (en) 2010-02-01 2014-12-25 Lab Bago S A Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
EP2486805A1 (en) * 2011-02-11 2012-08-15 Puratos N.V. An emulsion whippable at room-temperature
PL2671455T3 (pl) * 2011-04-14 2017-10-31 J Oil Mills Inc Frakcjonowany olej palmowy oraz kompozycja oleju i produkt spożywczy ją zawierający
CN102552168B (zh) * 2012-01-31 2013-08-07 杭州华东医药集团生物工程研究所有限公司 一种含有奥利司他的药物组合物及其制备方法
GB2501535A (en) 2012-04-26 2013-10-30 Sony Corp Chrominance Processing in High Efficiency Video Codecs
EA030444B1 (ru) * 2012-05-31 2018-08-31 Репрос Терапьютикс Инк. Способ лечения прогестеронзависимого состояния
WO2015063039A1 (en) 2013-10-28 2015-05-07 Nestec S.A. Monoacylglycerols for use in conjunction with a lipase inhibitor and/or diets low in fat and/or calories
CN115105476B (zh) * 2021-03-23 2023-11-14 山东新时代药业有限公司 一种奥利司他冻干口服制剂及其制备工艺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
FR2710264B1 (fr) * 1993-09-21 1995-12-08 Rocher Yves Biolog Vegetale Utilisation pour le traitement des peaux mixtes d'une quantité efficace de substances actives.
AU5185398A (en) * 1996-12-04 1998-06-29 James S Pincott Process and apparatus for making crumb rubber from scrap tyres
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
NZ336755A (en) 1997-02-05 2001-06-29 F Use of gastrointestinal lipase inhibitors in particular tetrahydrolipstatin (orlistat)
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
WO2000009123A1 (en) * 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors and chitosan
WO2000009122A1 (en) 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas

Also Published As

Publication number Publication date
ATE285783T1 (de) 2005-01-15
HRP20020206B1 (en) 2011-02-28
WO2001019378A3 (en) 2001-05-10
PL199869B1 (pl) 2008-11-28
ES2233444T3 (es) 2005-06-16
IL148570A (en) 2007-03-08
RU2248218C2 (ru) 2005-03-20
CN1373659A (zh) 2002-10-09
MXPA02002662A (es) 2002-07-30
PT1216048E (pt) 2005-04-29
AU7517700A (en) 2001-04-17
HK1049798A1 (en) 2003-05-30
PE20010661A1 (es) 2001-06-25
BRPI0013940B1 (pt) 2016-06-21
JP4217017B2 (ja) 2009-01-28
RS50373B (sr) 2009-11-10
SI1216048T1 (en) 2005-06-30
EP1216048B1 (en) 2004-12-29
EP1216048A2 (en) 2002-06-26
HUP0202762A3 (en) 2005-04-28
HRP20020206A2 (en) 2004-04-30
DE60017156T2 (de) 2006-01-05
NO328889B1 (no) 2010-06-07
NO20021205D0 (no) 2002-03-12
CZ20021277A3 (cs) 2003-04-16
MA26817A1 (fr) 2004-12-20
BR0013940A (pt) 2002-05-14
AR025609A1 (es) 2002-12-04
TR200200605T2 (tr) 2002-08-21
US6703369B1 (en) 2004-03-09
MY127430A (en) 2006-11-30
PL356154A1 (en) 2004-06-14
MEP90908A (en) 2011-12-20
NO20021205L (no) 2002-03-12
JP2003509373A (ja) 2003-03-11
ZA200201249B (en) 2003-07-30
KR20020060177A (ko) 2002-07-16
AU769016B2 (en) 2004-01-15
DE60017156D1 (de) 2005-02-03
CA2383036A1 (en) 2001-03-22
RU2002107450A (ru) 2004-01-10
NZ517396A (en) 2003-10-31
HK1049798B (zh) 2005-08-05
WO2001019378A2 (en) 2001-03-22
IL148570A0 (en) 2002-09-12
CN1197554C (zh) 2005-04-20
CO5210857A1 (es) 2002-10-30
ME00675B (me) 2011-12-20
HUP0202762A2 (hu) 2003-01-28
JO2300B1 (en) 2005-09-12
CZ301844B6 (cs) 2010-07-07
HU229037B1 (en) 2013-07-29
KR100523879B1 (ko) 2005-10-26
YU13602A (sh) 2006-01-16
CA2383036C (en) 2006-01-10
GC0000259A (en) 2006-11-01

Similar Documents

Publication Publication Date Title
GC0000259A (en) Solid lipid formulations
SG79255A1 (en) Pharmaceutical formulations
GB9804013D0 (en) Formulations
HUP0202235A3 (en) Preserved pharmaceutical formulations
AU5139600A (en) Nutritional formulations
EP1154755A4 (en) Liposomes FORMULATIONS
EG22674A (en) Ectroparasiticidal aquequs suspension formulations
HUP0201220A3 (en) Adjuvant combination formulations
EP1173216A4 (en) PHARMACEUTICAL FORMULATIONS
GB9923045D0 (en) New oral formulations
GB9806312D0 (en) Novel formulations
GB9815002D0 (en) Formulations
GB9815001D0 (en) Formulations
GB9906126D0 (en) Pharmaceutical formulations
GB9930578D0 (en) Pharmaceutical formulations
IL149635A0 (en) Solid preparation
GB9810181D0 (en) Novel formulations
GB9910118D0 (en) Formulations
GB9909079D0 (en) Novel formulations
GB9909080D0 (en) Novel formulations
GB9828205D0 (en) Pharmaceutical formulations
GB9823192D0 (en) Pharmaceutical formulations
GB9816558D0 (en) Pharmaceutical formulations
GB9817429D0 (en) Pharmaceutical formulations
GB9805931D0 (en) Pharmaceutical formulations